Gregory Alan Otterson
#161,119
Most Influential Person Now
Gregory Alan Otterson's AcademicInfluence.com Rankings
Gregory Alan Ottersonmedical Degrees
Medical
#3244
World Rank
#3703
Historical Rank
Oncology
#226
World Rank
#234
Historical Rank

Gregory Alan Ottersonphilosophy Degrees
Philosophy
#9296
World Rank
#12834
Historical Rank
Logic
#6280
World Rank
#7786
Historical Rank

Download Badge
Medical Philosophy
Gregory Alan Otterson's Degrees
- Doctorate Medicine Johns Hopkins University
- PhD Biomedical Sciences Johns Hopkins University
Why Is Gregory Alan Otterson Influential?
(Suggest an Edit or Addition)Gregory Alan Otterson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden (2018) (2193)
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. (2015) (1280)
- Non-small cell lung cancer clinical practice guidelines in oncology. (2006) (1010)
- Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology (2017) (805)
- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients (2016) (509)
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. (2019) (490)
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. (2021) (423)
- Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (411)
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. (2018) (411)
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. (2016) (382)
- Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial (2011) (380)
- Non-Small Cell Lung Cancer, Version 6.2015. (2015) (373)
- Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. (1998) (366)
- First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers (2019) (364)
- Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. (1994) (355)
- Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. (1996) (350)
- Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines (2013) (313)
- Acetylation of p53 at Lysine 373/382 by the Histone Deacetylase Inhibitor Depsipeptide Induces Expression of p21Waf1/Cip1 (2006) (287)
- Methylation of Adjacent CpG Sites Affects Sp1/Sp3 Binding and Activity in the p21Cip1 Promoter (2003) (282)
- Non-small cell lung cancer. (2012) (277)
- Non-small cell lung cancer. Clinical practice guidelines in oncology. (2004) (269)
- Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). (2014) (266)
- MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. (2008) (265)
- Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. (2019) (241)
- Non-small cell lung cancer, version 2.2013. (2013) (234)
- The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. (2003) (232)
- DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. (2001) (228)
- CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine. (1995) (227)
- Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. (2014) (209)
- Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration (2019) (206)
- Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. (2019) (194)
- Molecular pathways and therapeutic targets in lung cancer (2014) (186)
- MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. (2009) (178)
- A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. (2003) (166)
- Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. (2020) (158)
- Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. (2006) (155)
- Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. (2006) (155)
- Non-small cell lung cancer, version 1.2015. (2014) (154)
- Lung cancer screening: Clinical practice guidelines in oncology (2012) (154)
- 5-Aza-2′-deoxycytidine Activates the p53/p21Waf1/Cip1 Pathway to Inhibit Cell Proliferation* (2004) (154)
- A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. (2002) (149)
- Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (147)
- The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2) (2017) (134)
- Lung cancer exosomes as drivers of epithelial mesenchymal transition (2016) (129)
- Romidepsin: a novel histone deacetylase inhibitor for cancer (2011) (128)
- RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. (1994) (127)
- Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). (2015) (126)
- Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. (2006) (124)
- Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. (1995) (120)
- Increased expression of unmethylated CDKN2D by 5-aza-2′-deoxycytidine in human lung cancer cells (2001) (116)
- Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs (2007) (116)
- Pulmonary neuroendocrine/carcinoid tumors (2009) (116)
- A Novel Classification of Lung Cancer into Molecular Subtypes (2012) (114)
- Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines. (2015) (106)
- Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients (2016) (106)
- Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. (2004) (106)
- Non-small cell lung cancer. (2010) (103)
- Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis (2019) (101)
- Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function. (1997) (101)
- Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study (2021) (91)
- Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. (2009) (90)
- Global methylation profiling of lung cancer identifies novel methylated genes. (2001) (88)
- Protein expression and functional analysis of the FHIT gene in human tumor cells. (1998) (88)
- Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer (2010) (87)
- Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model. (2019) (87)
- Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding (1997) (86)
- The N-terminal domain of c-Myc associates with alpha-tubulin and microtubules in vivo and in vitro (1995) (85)
- Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). (2001) (81)
- Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer (2012) (81)
- Smoking status and survival in the national comprehensive cancer network non–small cell lung cancer cohort (2013) (81)
- First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. (2021) (79)
- HDAC Inhibitors Act with 5-aza-2′-Deoxycytidine to Inhibit Cell Proliferation by Suppressing Removal of Incorporated Abases in Lung Cancer Cells (2008) (77)
- NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. (2016) (76)
- Unraveling the epigenetic code of cancer for therapy. (2007) (75)
- MicroRNAs in the Pathogenesis of Lung Cancer (2009) (72)
- Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers (2019) (69)
- A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-α, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non–Small Cell Lung Cancer (2004) (69)
- Strong Inverse Correlation Between MicroRNA-125b and Human Papillomavirus DNA in Productive Infection (2010) (66)
- CT Gray-Level Texture Analysis as a Quantitative Imaging Biomarker of Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma of the Lung. (2015) (66)
- A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. (2012) (65)
- Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) (2010) (65)
- Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). (2012) (63)
- Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial. (2018) (62)
- Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With None–Small-cell Lung Cancer (2018) (59)
- Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. (2002) (59)
- Differential specificity for binding of retinoblastoma binding protein 2 to RB, p107, and TATA-binding protein (1994) (57)
- Partial inactivation of the RB product in a family with incomplete penetrance of familial retinoblastoma and benign retinal tumors. (1994) (56)
- Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (2020) (55)
- A pilot test of a combined tobacco dependence treatment and lung cancer screening program. (2012) (54)
- Thymomas and thymic carcinomas (2013) (54)
- Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report (2012) (53)
- CALGB 30704 (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2014) (51)
- Relationship between Overall Survival and Response or Progression‐Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD‐1/PD‐L1 Antibodies (2016) (51)
- Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non–small cell lung cancer patients with KRAS‐activated tumors (2016) (51)
- Lung cancer screening. (2003) (50)
- Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. (2013) (50)
- The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non–Small Cell Lung Cancer (2018) (50)
- Bone morphogenetic protein 3B silencing in non-small-cell lung cancer (2004) (50)
- Aberrant DNA Methylation of OLIG1, a Novel Prognostic Factor in Non-Small Cell Lung Cancer (2007) (49)
- The Self-regulation Model of Illness Applied to Smoking Behavior in Lung Cancer (2009) (47)
- Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer (2017) (47)
- Detection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons. (2013) (47)
- Liquid biopsy for lung cancers: an update on recent developments. (2019) (47)
- Crizotinib in Patients With MET-Amplified NSCLC. (2021) (47)
- Clinical significance of the FV:Q506 mutation in unselected oncology patients. (1996) (46)
- Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors (2013) (44)
- Agents to treat BRAF-mutant lung cancer (2019) (44)
- Comparative effectiveness of stereotactic radiosurgery versus whole‐brain radiation therapy for patients with brain metastases from breast or non–small cell lung cancer (2016) (43)
- A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602) (2010) (42)
- Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients. (2015) (41)
- Temperature-sensitive RB mutations linked to incomplete penetrance of familial retinoblastoma in 12 families. (1999) (41)
- Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells. (2006) (41)
- A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871 (2007) (41)
- Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. (2003) (40)
- CDKN2 in HPV‐positive and HPV‐negative cervical‐carcinoma cell lines (1995) (40)
- Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model. (2018) (39)
- Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD‐L1 and PD‐1 in Thymoma and Thymic Carcinoma (2018) (39)
- RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer (1998) (39)
- Incorporation of photodynamic therapy as an induction modality in non‐small cell lung cancer (2006) (36)
- An epigenetic mechanism for capecitabine resistance in mesothelioma. (2006) (35)
- MA04.02 Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study (2017) (35)
- P21 response to DNA damage induced by genistein and etoposide in human lung cancer cells. (2003) (34)
- Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management. (2012) (33)
- A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. (2004) (33)
- Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice (2002) (32)
- High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer. (2013) (32)
- Stable binding to E 2 F is not required for the retinoblastoma protein to activate transcription , promote differentiation , and suppress tumor cell growth (1997) (32)
- Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. (2008) (31)
- OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer (2018) (31)
- A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors (2013) (30)
- Fanconi Anemia Repair Pathway Dysfunction, a Potential Therapeutic Target in Lung Cancer (2014) (29)
- Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. (2015) (29)
- Inhibition of cyclin D-CDK 4 / CDK 6 activity is associated with an E 2 F-mediated induction of cyclin kinase inhibitor activity ( human papillomaviruses / cervical cancer / E 7 oncoprotein / retinoblastoma protein ) (29)
- Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications (2019) (28)
- MicroRNA‐34a is an important component of PRIMA‐1‐induced apoptotic network in human lung cancer cells (2010) (28)
- Functional analysis at the Cys706 residue of the retinoblastoma protein. (1992) (28)
- The search for an optimal DNA, RNA, and protein detection by in situ hybridization, immunohistochemistry, and solution-based methods. (2010) (28)
- A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer (2016) (28)
- A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced Non–Small-Cell Lung Cancer (2014) (26)
- Genetic etiology of lung cancer. (1992) (25)
- First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions. (2012) (25)
- Altered p16INK4 and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer (2012) (25)
- Phase II Evaluation of Docetaxel-Modulated Capecitabine in Previously Treated Patients with Non–Small Cell Lung Cancer (2005) (25)
- NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation (2014) (24)
- Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. (2013) (24)
- A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. (2004) (24)
- Advances in epigenetic therapeutics with focus on solid tumors (2021) (23)
- Erlotinib in African Americans With Advanced Non–Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses (2014) (22)
- Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. (2015) (22)
- A psychometric analysis of quality of life tools in lung cancer patients who smoke. (2009) (22)
- First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced Non-Small Cell Lung Cancer With Tumor PD-L1 ≥ 1%: Patient-Reported Outcomes From CheckMate 227 Part 1. (2021) (22)
- A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer (2016) (21)
- RB-mediated tumor suppression of a lung cancer cell line is abrogated by an extract enriched in extracellular matrix. (1993) (21)
- Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice (2008) (19)
- Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer. (2010) (19)
- Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit. (2016) (19)
- Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma (2010) (18)
- Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer (2010) (18)
- A 'core ATPase', Hsp70-like structure is conserved in human, rat, and C. elegans STCH proteins. (1997) (18)
- A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer. (2012) (17)
- Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database (2018) (17)
- Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis. (2017) (17)
- Localization of STCH to human chromosome 21q11.1. (1995) (16)
- Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. (2021) (15)
- Non – Small Cell Lung Cancer, Version 3.2022 (2022) (15)
- Incorporation of Antiangiogenic Therapy Into the Non-Small-Cell Lung Cancer Paradigm. (2016) (15)
- Abstract CT195: Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response (2019) (14)
- Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer (2014) (14)
- Impact of immune-related adverse events (irAE) on overall survival (OS) in patients treated with immunotherapy for non-small cell lung cancer (NSCLC). (2017) (14)
- Small cell lung cancer in never smokers: report of two cases. (2010) (14)
- Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy. (2017) (14)
- Phase II study of oxaliplatin (O) and paclitaxel (T) in advanced Non-Small Cell Lung Cancer (NSCLC) (2000) (13)
- Multicenter Phase II Trial of Motexafin Gadolinium and Pemetrexed for Second-Line Treatment in Patients with Non-small Cell Lung Cancer (2011) (12)
- Expression of a Mutant p53 Results in an Age-Related Demographic Shift in Spontaneous Lung Tumor Formation in Transgenic Mice (2009) (12)
- 41 Clinical activity of BIND-014 (docetaxel nanoparticles for injectable suspension) as second-line therapy in patients (pts) with Stage III/IV non-small cell lung cancer (2014) (12)
- Randomized Phase II Study of Palifermin for Reducing Dysphagia in Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Unresectable Non-small Cell Lung Cancer (2012) (12)
- Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. (2021) (11)
- Cell cycle regulation of the G0/G1 transition in 5-fluorouracil-sensitive and -resistant human colon cancer cell lines. (2000) (11)
- Alternative splicing of the RBP1 gene clusters in an internal exon that encodes potential phosphorylation sites. (1993) (11)
- Phase 1 trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors (2005) (11)
- Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227 (2018) (10)
- Overexpression of Rad51C splice variants in colorectal tumors (2014) (10)
- Phase I study of 5-aza-2’-deoxycytidine in combination with valproic acid in patients with NSCLC (2008) (10)
- Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor. (1993) (10)
- Rad51C-ATXN7 fusion gene expression in colorectal tumors (2016) (10)
- CLO20-054: A Phase 2 Trial of Nivolumab and Temozolomide in Advanced Neuroendocrine Tumors (NETs): Interim Efficacy Analysis (2020) (10)
- Metastatic Squamous Cell Carcinoma Component from an Adenosquamous Carcinoma of the Lung with Identical Epidermal Growth Factor Receptor Mutations (2015) (10)
- A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. (2012) (10)
- Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer (2017) (10)
- Thalidomide and celecoxib as potential modulators of irinotecan’s activity in cancer patients (2006) (9)
- Phase I/II Dose-Finding Study of Crizotinib (CRIZ) in Combination with Erlotinib (E) in Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC) (2012) (9)
- Clinical and Metabolic Parameters in Non-Small Cell Lung Carcinoma and Colorectal Cancer Patients with and without KRAS Mutations (2014) (9)
- A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC (2020) (9)
- Safety and pharmacokinetics (PK) of AMG 706 in combination with panitumumab and gemcitabine-cisplatin in patients (pts) with advanced cancer (2007) (9)
- A pilot trial of G 3139 , a bcl-2 antisense oligonucleotide , and paclitaxel in patients with chemorefractory small-cell lung cancer (2002) (9)
- Increased NQO1 but Not c-MET and Survivin Expression in Non-Small Cell Lung Carcinoma with KRAS Mutations (2014) (9)
- Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies (2009) (9)
- Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC). (2012) (8)
- CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM). (2010) (8)
- Evaluating the effectiveness of darbepoetin alfa 300 mcg Q3W for the treatment of chemotherapy-induced anemia (2005) (8)
- A Phase I Clinical and Pharmacokinetic Study of Fenretinide Combined with Paclitaxel and Cisplatin for Refractory Solid Tumors (2005) (8)
- CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC). (2012) (8)
- Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer (2020) (8)
- Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer. (2020) (8)
- EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. (2018) (8)
- Nontoxic Suramin as a Chemosensitizer in Patients: Dosing Nomogram Development (2006) (8)
- The N-Terminal Domain of c-Myc Associates with a-Tubulin and Microtubules In Vivo and In Vitro (1995) (8)
- Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy (2021) (7)
- Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses. (2013) (7)
- Effect of concomitant medications on overall survival in patients with cancer undergoing immunotherapy. (2019) (7)
- Abstract 5500: Inhibition of poly(ADP-ribose) polymerase in lung cancer cells with defective Fanconi anemia (FA) pathway (2011) (7)
- RT-PCR heteroduplex analysis permits differentiation of transgene and host gene expression in a transgenic animal model. (2002) (7)
- Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. (2019) (7)
- Immunotherapy in inoperable stage III non-small cell lung cancer: a review (2019) (7)
- Abstract CT113: Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC (2018) (7)
- Malignant pleural mesothelioma. (2015) (6)
- Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events (2021) (6)
- O.02 Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response (2019) (6)
- NCCN Non – Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (2010) (6)
- Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy. (2022) (6)
- Thymic malignancies. (2010) (6)
- A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2015) (6)
- Proton pump inhibitor use (PPI) in patients treated with immune checkpoint inhibitors (ICI) for advanced cancer: Survival and prior therapy. (2021) (6)
- Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer (2017) (6)
- Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer (2011) (6)
- Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy. (2009) (6)
- Bone morphogenetic protein 3 B silencing in non-small-cell lung cancer (2004) (6)
- Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival (2021) (5)
- A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors (2012) (5)
- Utilization of adjuvant therapy among completely resected non-small cell lung cancer (NSCLC) patients in the National Comprehensive Cancer Network (NCCN) Outcomes Database Project. (2010) (5)
- A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC). (2013) (5)
- Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials (2009) (5)
- P-229 Phase II evaluation of low dose suramin as a modulator of paclitaxel/carboplatin (P/C) in non-small cell lung cancer (NSCLC) patients (2003) (5)
- Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib. (2016) (5)
- MA08.01 A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma (2017) (5)
- Modulation of chemotherapy resistance with low dose suramin in refractory non-small cell lung cancer (NSCLC) patients: A phase I study of sequential non-cross resistant chemotherapy (2005) (4)
- Preoperative bevacizumab in combination with paclitaxel and carboplatin in surgically resectable non-small cell lung cancer. (2011) (4)
- Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Non-Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical Considerations. (2020) (4)
- Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. (2022) (4)
- Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC (2022) (4)
- Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers (2020) (4)
- Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells. (2020) (4)
- P76.62 RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC (2021) (4)
- Phase 2 Trial of Nab-Paclitaxel Plus Carboplatin for Advanced NSCLC in Patients at Risk of Bleeding From VEGF Directed Therapies (2014) (4)
- Abstract PO-003: CRESTONE – Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) Fusions – A phase 2 study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210) (2020) (4)
- Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA – N 2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy † (2015) (4)
- Mechanisms of DNA Demethylating Drugs Against Cancer Progression (2005) (3)
- Malignant Melanoma Presenting as Thoracic Midline Malignancy: Clinicopathologic and Molecular Features (2017) (3)
- Phase II study of low dose suramin as a sensitizer of paclitaxel/carboplatin (P/C) in non small cell lung cancer (NSCLC). (2004) (3)
- Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy. (2019) (3)
- Immune related adverse events across cancer types: Incidence, risk factors and survival. (2018) (3)
- Effect of dichloroacetate in combination with chemotherapy on human lung cancer cells (2008) (3)
- A Phase I / II Study of LY 900003 , an Antisense Inhibitor of Protein Kinase C-, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non – Small Cell Lung Cancer (2004) (3)
- Abstract LB-225: Phase 2 Trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF directed therapies (2012) (3)
- 67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1 (2020) (3)
- Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency. (2020) (3)
- Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy. (2020) (3)
- P40.15 Proton Pump Inhibitors, Prior Therapy and Survival in Patients Treated With Immune Checkpoint Inhibitors for Advanced NSCLC (2021) (3)
- Mutational Profiling of Second Primary Lung Cancers in Patients Who Have Received Radiation for the Treatment of Hodgkin's Disease (2015) (3)
- OA 18.02 The Landscape of Alteration of DNA Integrity-Related Genes and Their Association with Tumor Mutation Burden in Non-Small Cell Lung Cancer (2017) (3)
- Photodynamic therapy (PDT) may provide effective palliation in the treatment of primary tracheal carcinoma: a small case series. (2012) (3)
- Apricot-l: Results of a biomarker-based phase II randomized placebo-controlled study of apricoxib in combination with erlotinib in non-small cell lung cancer (NSCLC) patients. (2011) (2)
- Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival (2022) (2)
- Type of TP53 mutation influences oncogenic potential and spectrum of associated K‐ras mutations in lung‐specific transgenic mice (2019) (2)
- The role of methylation leading to capecitabine resistant malignant mesothelioma. (2006) (2)
- Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (2020) (2)
- 5-Aza-2 (cid:1) -deoxycytidine Activates the p53/p21 Waf1/Cip1 Pathway to Inhibit Cell Proliferation* (2004) (2)
- A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC). (2021) (2)
- Y-chromosome status identification suggests a recipient origin of posttransplant non-small cell lung carcinomas: chromogenic in situ hybridization analysis. (2014) (2)
- Abstract A99: Phase I trial of veliparib or mitomycin C + veliparib in pts with Fanconi anemia pathway (FA) repair defects. (2011) (2)
- Results of a phase I study of inhaled doxorubicin combined with docetaxel and cisplatin for advanced non-small cell lung cancer (2005) (2)
- Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2. (2020) (2)
- Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors? (2018) (2)
- A single center review of the experience with mitomycin C (MMC) and the risk of thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS) (2007) (2)
- CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210). (2021) (2)
- Erratum: Smoking status and survival in the national comprehensive cancer network nonsmall cell lung cancer cohort (Cancer (doi: 10.1002/cncr.27824)) (2013) (1)
- 6MO Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up (2022) (1)
- An Evaluation of the Effectiveness of Darbepoetin alfa 300 mcg Every 3 Weeks (Q3W) on Clinical Outcomesin Cancer Patients with Chemotherapy-Induced Anemia. (2004) (1)
- PS01.09 Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598 (2021) (1)
- P21.02 Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation (2021) (1)
- Racial/Ethnic Disparities in the Delivery of Curative Intent Therapy in Patients with Stage III Non-small Cell Lung Cancer Not Treated Surgically: An Analysis of the National Cancer Database (2018) (1)
- A multicenter randomized phase III trial of customized chemotherapy versus standard of care for first-line treatment of elderly patients with advanced non-small cell lung cancer (EPIC). (2012) (1)
- Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0). (2015) (1)
- Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have Kras or EGFR-activated tumors. (2010) (1)
- Molecular Profiling by Next-Generation Sequencing in Nonsmall Cell Lung Cancer (2013) (1)
- 540P Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy (2020) (1)
- Phase II randomized study of the safety, efficacy, metabolism, and molecular targets of erlotinib in African Americans (AA) with NSCLC. (2010) (1)
- Neutrophil to lymphocyte ratio, PD-L1 expression, and survival in patients with advanced non-small cell lung cancer receiving first-line immune checkpoint inhibitor therapy. (2020) (1)
- Effectiveness of Darbepoetin alfa Administered Every 3 Weeks on Clinical Outcomes in Patients with Hematologic Malignancies and Chemotherapy-Induced Anemia. (2005) (1)
- Initiation of targeted therapy based on ctDNA only in metastatic NSCLC. (2019) (1)
- Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small cell lung cancer (NSCLC) that subsequently progresses. (2011) (1)
- Increased Posttreatment Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Marker for Worse Overall Survival in Patients Receiving Concurrent Chemoradiation for Lung Cancer (2016) (1)
- Everolimus in thymic epithelial tumors: practical considerations (2018) (1)
- Aggressive end-of-life (EOL) chemotherapy (CT) use in metastatic non-small cell lung cancer (mNSCLC): A National Comprehensive Cancer Network (NCCN) outcomes database analysis. (2011) (1)
- A phase II study of atezolizumab and cobimetinib in PD-1/PD-L1 inhibitor resistant or refractory non-small cell lung cancer: ETCTN #10166. (2020) (1)
- Abstract 559: Inhibition of pro-survival pathways in lung cancer cells with functional defects in the Fanconi Anemia pathway (2015) (1)
- Enhancement of cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) with lenalidomide in advanced solid tumors: A phase 1 trial. (2014) (1)
- Is immunotherapy toxicity associated with improved overall survival among older adults with advanced cancer? (2019) (1)
- P1.01-71 Bone Metastases and Skeletal-Related Events in Patients with Metastatic NSCLC Treated with ICIs: A Multi-Institutional Study (2019) (1)
- Abstract 748: Genomic characterization of recurrent small cell lung cancer through research autopsy reveals clonal diversity and candidate driver of chemoresistance (2019) (1)
- 603 Phase II Trial of Oncolytic Reovirus in Combination with Chemotherapy in NSCLC Pts with Kras Activated Tumors (2012) (1)
- Immune pneumonitis-related treatment discontinuations and outcomes in metastatic non-small cell lung cancer treated with nivolumab: A pooled analysis from a multi-institutional international collaboration. (2019) (1)
- Phase II trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF-directed therapies. (2010) (1)
- P48.19 Outcomes of Patients Treated with First Line Immunotherapy Plus Chemotherapy for ES-SCLC: Real World Outcomes from a Tertiary Academic Center (2021) (1)
- NCCN Non – Small Cell Lung Cancer , Version 1 . 2015 Clinical Practice Guidelines in Oncology (2014) (1)
- The effectiveness of darbepoetin alfa administered at 300 mcg every 3 weeks on clinical outcomes in elderly patients with chemotherapy-induced anemia. (2006) (1)
- P2-230: A Phase I Study of Nontoxic Suramin As A Chemosensitizer In Pretreated/Refractory Non-Small Cell Lung Cancer (NSCLC) Patients (2007) (1)
- Cost Consequence Analysis Of Different Gene Mutation Testing Modalities For Braf V600E Mutation In Advanced Non-Small Cell Lung Cancer Using A Decision Analytic Model (2017) (1)
- Retrospective analysis of the impact of age on overall survival in patients with non-small cell lung cancer. (2012) (1)
- 557 PRMT5, a Novel Epigenetic Target in Lung Cancers (2012) (1)
- Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report (2023) (1)
- 615 Preliminary results of a phase I/II study of inhaled doxorubicin combined with docetaxel and cisplatin for advanced non-small cell lung cancer (2004) (0)
- Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy” (2021) (0)
- Computed tomography (CT) imaging features in early-stage lung adenocarcinoma differentiating exon 19 and exon 21 epidermal growth factor receptor (EGFR) mutated tumors. (2014) (0)
- Establishment and characterization of a line of transgenic mice harboring a lung specific human type II p53(175H) mutation (2005) (0)
- End of life resource utilization among patients receiving immunotherapy for advanced cancer. (2018) (0)
- Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy. (2023) (0)
- Bone modifying agents and skeletal related events in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. (2021) (0)
- PRMT 5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT 5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy Topic : Targets for Treatment Prediction (2016) (0)
- Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicity in Patients Receiving Concurrent Chemoradiation for Lung Cancer (2016) (0)
- Rad51C-ATXN7 fusion gene expression in colorectal tumors (2016) (0)
- Non-small cell lung cancer. (2008) (0)
- Research Highlights. (2012) (0)
- A single institution experience of lung cancer treatment in octogenarians (2007) (0)
- Comprehensive Next-Generation Sequencing Analysis is Recommended for the Management of Patients With Melanoma. (2017) (0)
- Platelets impact the responsiveness of immune checkpoint blockade therapy in solid tumors. (2020) (0)
- MR-Predictive Assay in Preoperative Lung Cancer Therapy (2012) (0)
- Abstract #5460: Erlotinib in African Americans with lung cancer: a prospective, clinical, molecular, pharmacokinetic and pharmacogenetic characterization (2009) (0)
- Malignant Pleural MesotheliomaPractice Guidelines in Oncology (2012) (0)
- Correlation of epidermal growth factor receptor (EGFR) mutation profile with computed tomography (CT) imaging features in lung adenocarcinomas. (2013) (0)
- P3.02c-056 Interim Results From the Phase I Study of Nivolumab + nab-Paclitaxel + Carboplatin in Non-Small Cell Lung Cancer (NSCLC): Topic: IT (2017) (0)
- O-309 Photodynamic therapy (PDT) can be incorporated into the multimodality treatment of loco-regionally advanced non-small cell lung cancer (NSCLC) with obstructive lesions (2003) (0)
- Emerging biomarkers for checkpoint inhibitors in thymic epithelial tumors (2019) (0)
- Abstract 4221: Mutations in Rad51C in colon tumors. (2013) (0)
- Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis. (2023) (0)
- EP08.01-098 Evaluating Risk Factors for Pneumonitis in Stage III NSCLC Patients Receiving Durvalumab after Definitive Chemoradiation (2022) (0)
- The experience of first-year hematology and oncology fellows after implementing a wellness chief fellow at an academic cancer center. (2020) (0)
- Tumor mutation status of Hodgkin lymphoma survivors with secondary lung adenocarcinoma. (2013) (0)
- EP14.05-004 Temozolomide and Atezolizumab as Second Line Treatment for Extensive Stage Small Cell Lung Cancer: A Randomized, Multi-Cohort Phase 2 Trial (2022) (0)
- A cell cycle-related RNA expression signature of neoantigen burden in lung adenocarcinoma. (2018) (0)
- Early changes in lymphocyte/monocyte ratio on-treatment as a prognostic marker to predict overall survival in patients with advanced cancer treated with immune checkpoint inhibitors (2021) (0)
- A phase I study of prolonged infusion of triapine in combination with a fixed-dose rate of gemcitabine in patients with advanced solid tumors. (2010) (0)
- Immune checkpoint inhibitor induced hepatitis: Risk factors, outcomes, and impact on survival. (2021) (0)
- EML4-ALK in NSCLC: The OSU Experience. (2011) (0)
- Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration (2020) (0)
- 1249 Treatment interruptions for immune related adverse events and overall survival in patients with non-small cell lung cancer (NSCLC) treated with first line immune checkpoint inhibitors (ICI) (2022) (0)
- Retrospective analysis of pulmonary neuroendocrine/carcinoid tumors at Ohio State University (2007) (0)
- P3.17-20 Impact of Significant Primary Tumor Size Reduction on Radiation Dose to Normal Structures in Patients Receiving Definitive Chemoradiotherapy (2018) (0)
- 244 Repeated Stereotactic Radiosurgery for Recurrent Brain Metastases is Safe and Effective (2009) (0)
- Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer. (2023) (0)
- EP16.03-009 Patterns of KEAP1 Genomic Co-alterations in Advanced Non-small Cell Lung Cancer Identified by Plasma-Based Genyotyping (2022) (0)
- 78P Association between obesity, sex, and overall survival in patients with metastatic cancers treated with first- or second-line immune checkpoint inhibitors (2022) (0)
- P09.13 Bone Metastases and Overall Survival in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Pembrolizumab (2021) (0)
- Abstract 3866: Potential oncogenic function of Rad51C splice variant in colorectal tumors (2015) (0)
- Abstract A76: Enhancement of cetuximab-induced antibody-dependent cellular cytotoxicity with lenalidomide in advanced solid tumors: A Phase I trial. (2013) (0)
- P-692 Photodynamic therapy (PDT) for primary tracheal carcinoma (2003) (0)
- Abstract 4438: Promoter hypermethylation status of Fanconi Anemia (FA) pathway genes FANCF, FANCL and FANCS in non-small cell lung cancer (NSCLC) (2016) (0)
- EP08.01-062 Body Mass Index, Immune Related Adverse Events, and Survival in Patients with Metastatic Non-small Cell Lung Cancer Treated with Immunotherapy (2022) (0)
- P-306 Retrospective analysis of octogenarians with lung cancer (2005) (0)
- Phase II and pharmacogenetic study of docetaxel (D) and capecitabine (C) in chemonaive non-small cell lung cancer (NSCLC) patients (pts) (2008) (0)
- P-533 Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer (2003) (0)
- Immune checkpoint inhibitor-related thrombocytopenia: Incidence, risk factors, and effect on overall survival. (2021) (0)
- MA 06.08 Lung Cancer Patients with Germline Mutation: A Retrospective Study (2017) (0)
- PV-0040: Patterns of care for the elderly with non-surgically treated stage III non-small cell lung cancer (2018) (0)
- NSCLC Treated at NCCN Institutions With NCCN Guidelines for Patients Diagnosed With Metastatic First-Line Systemic Therapy Practice Patterns and Concordance (2012) (0)
- Abstract 4682: Compensatory activation of alternative DNA repair pathways following exposure to the PARP Inhibitor ABT-888in vitroand in patients with solid malignancies (2012) (0)
- Abstract 4246: Promoter hypermethylation and gene expression of FANCF in non-small cell lung cancer (NSCLC). (2013) (0)
- P1.04-15 Smoking Status Is Not a Replacement Biomarker for Tumor Mutation Burden in Non-Small Lung Cancer (2019) (0)
- P-128 Establishment and characterization of a line of transgenic miceharboring a lung specific human type II p53(175H) mutation; a potential model of human disease (2005) (0)
- P2.01-092 PRMT5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy: Topic: Targets for Treatment Prediction (2017) (0)
- MicroRNA 133B Sensitizes Non Small Cell Lung Cancer to Chemotherapeutic Agents by Targeting BCLw. (2009) (0)
- P3.03-007 LCMC2: Expanded Profiling of Lung Adenocarcinomas Identifies ROS1 and RET Rearrangements and TP53 Mutations as a Negative Prognostic Factor (2017) (0)
- Abstract 4740: Establishment of P53 mutant type specific spontaneous lung tumor in transgenic mice for treatment (2012) (0)
- CGE23-070: Baseline Neutrophil to Lymphocyte Ratio and Its Change Over Time Predict Overall Survival in Metastatic Non–Small Cell Lung Cancer Patients Who Received First Line Pembrolizumab Therapy (2023) (0)
- O-142 Phase I and pharmacokinetic trial of inhalational doxorubicin (Resmycin™) (2003) (0)
- Changes in lymphocyte/monocyte ratio, prognostic marker to predict overall survival in patients with advanced cancer treated with immune checkpoint inhibitor. (2020) (0)
- Abstract 4365: Sensitivity of small cell lung cancer cells with defective Fanconi Anemia (FA) pathway to BCL2 inhibitors.. (2013) (0)
- Valproic acts as an HDAC inhibitor in cells and works synergistically with the DNMT inhibitor, 5-aza-2′-deoxycytidine (2004) (0)
- Re-evaluating the neutrophil-to-lymphocyte ratio: Machine learning-based variable selection for predicting survival at twelve months in late-stage cancer patients receiving immunotherapy. (2019) (0)
- A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations. (2023) (0)
- Lung Cancer ScreeningPractice Guidelines in Oncology (2012) (0)
- P78.05 Patterns of irAE During First Line Pembrolizumab for NSCLC: Incidence, Risk Factors, and Impact on Clinical Outcome (2021) (0)
- Recurrent and de-novo autoimmune hemolytic anemia in patients treated with immunotherapy for advanced cancer. (2019) (0)
- Cellular Localization of Protein Arginine Methyltransferase-5 Correlates With Grade of Pulmonary Neuroendocrine Tumors (2013) (0)
- PP01.25 Incidence and Timing of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor as Monotherapy or in Combination With Chemotherapy (2023) (0)
- Dynamic-Contrast Enhanced MR and Volume Regression Rate as a Preoperative Predictive Assay in Patients With Non-Small Cell Lung Cancer (2014) (0)
- Abstract 3750: Functional analysis of the Fanconi Anemia pathway in primary lung tumors (2010) (0)
- A Case of Mediastinal Carcinosarcoma With Beta-HCG Production and KRAS Mutation. (2023) (0)
- Commentary (Kosuri/Otterson): Coming to Grips With Hand-Foot Syndrome (2004) (0)
- Mutant type specific lung cancer models for individualized treatment (2006) (0)
- Expression of a mutant p53 in lung specific transgenic mice cause age-related demographic shift in lung tumor incidence (2007) (0)
- ‘A QUESTION OF INTENT: A Great American Battle with a Deadly Industry’ (2002) (0)
- Lung Cancer: Conference Highlights from the 2015 ASCO Annual Meeting (2015) (0)
- Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications (2020) (0)
- P75.12 Prognostic Value of Neutrophil to Lymphocyte Ratio in NSCLC Patients Receiving First Line Immune Checkpoint Inhibitor Therapy (2021) (0)
- NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. (2023) (0)
- Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598. (2021) (0)
- Advances in epigenetic therapeutics with focus on solid tumors (2021) (0)
- 442 Pre-treatment interstitial abnormalities is a risk factor for immune checkpoint inhibitor pneumonitis in patients with lung cancer (2022) (0)
- 48 Phase I study of inhaled doxorubicin combined with docetaxeland cisplatin for advanced non-small cell lung cancer (2005) (0)
- Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer (2017) (0)
- Abstract 854: Inhibition of PRMT5 results in radiosensitization in lung cancer cell lines (2014) (0)
- Immunohistochemical staining for programmed cell-death ligand 1 (PD-L1) in malignant thymoma and thymic carcinoma. (2017) (0)
- Abstract 4442: micoRNA in FA defective tumor (2017) (0)
- Abstract CT141: Phase I study of nivolumab (nivo) +nab-paclitaxel (nab-P) + carboplatin (C) in advanced NSCLC: safety and efficacy results (2016) (0)
- EP1.12-38 Retrospective Analysis of Immunotherapy Utilization in Advanced Small Cell Carcinoma at an Academic Cancer Center (2019) (0)
- Abstract A43: EGFR-targeted therapy in African Americans with advanced non-small cell lung cancer: A prospective clinical, pharmacogenetic, and pharmacokinetic study. (2012) (0)
- Inhaled corticosteroid use and risk of pneumonitis in patients treated with immune checkpoint inhibitors. (2020) (0)
- Abstract 2407: Investigation of Novel Rad51c-ATXN7 fusion gene in colorectal tumors (2014) (0)
- P79.04 A Phase 2 Trial of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer: Interim Efficacy Analysis. (2021) (0)
- 585 Phase 1 dose escalation trial of the selective A2B adenosine receptor antagonist PBF-1129 in patients with metastatic non-small cell lung cancer (mNSCLC) (2022) (0)
- A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as fi rst-line treatment in patients with advanced non-small-cell lung cancer (0)
- Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer (2023) (0)
- First-line systemic therapy in metastatic non-small cell lung cancer (mNSCLC) patients treated at National Comprehensive Cancer Network (NCCN) institutions: An analysis from the NCCN Oncology Outcomes Database Project. (2010) (0)
- Human mutant p53 lung cancer cells respond differently to PRIMA-1 induced apoptosis (2007) (0)
- Modulation of Radiation Response of Non-small Cell Lung Cancer Cells with Poly (ADP-Ribose) Polymerase Inhibitor: ABT-888 (2008) (0)
- OA 12.06 Plasma Genomic Profiling and Outcomes of Patients with MET Exon 14-Altered NSCLCs Treated with Crizotinib on PROFILE 1001 (2017) (0)
- Association of LAG-3 expression in circulating T cells and response to combination temozolomide (TMZ) and nivolumab (NIVO) in advanced neuroendocrine neoplasms (NENs): Results from an investigator-initiated phase 2 trial. (2022) (0)
- New treatment options and challenges for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer with brain metastases. (2017) (0)
- Low dose suramin as a chemosensitizer in patients: pharmacokinetics, identification and validation of a dosing nomogram (2005) (0)
- Abstract 5434: Combined BCL-2/XL and mTor inhibition promotes apoptosis in small cell lung cancer (2014) (0)
- Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database (2018) (0)
- Abstract 4082: Global miRNA expression changes induced by HDAC-42 and 5-azaCdr in lung cancer cells (2012) (0)
- OA12.04 Efficacy of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer after Chemo-Immunotherapy: A Phase 2 Trial. (2022) (0)
- A randomized, double-blind, placebo-controlled multicenter phase II study of the COX-2 inhibitor apricoxib (A) in combination with either docetaxel (doc) or pemetrexed (pem) in advanced non-small cell lung cancer (NSCLC) patients (pts) selected by urinary PGE-m suppression. (2012) (0)
- Protein Arginine Methyltransferase-5 as a Novel Epigenetic Target in Lung Cancer (2013) (0)
- P2.04-020 Expression Patterns and Prognostic Value of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma: Topic: Thymic Malignancies Clinical and Translational (2017) (0)
- A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms (2022) (0)
- Palifermin Reduces Dysphagia in Patients with Locally-advanced Unresected Non–small-cell Lung Cancer Undergoing Concurrent Chemoradiotherapy (2009) (0)
- Correction: Association between pre‑treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis. (2023) (0)
- Neutrophil-lymphocyte score: A novel prognostic scoring system that utilized the dynamic change of neutrophil, lymphocyte, and albumin and its comparison to other indices. (2020) (0)
- P-211 Phase II study of docetaxel in combination with capecitabine in patients with previously treated non-small cell lung cancer (NSCLC) (2003) (0)
- Comparative Effectiveness of Stereotactic Radiosurgery (SRS) Versus Whole Brain Radiation Therapy (WBRT) for Patients With Brain Metastases From Non-Small Cell Lung Cancer (NSCLC) (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Gregory Alan Otterson?
Gregory Alan Otterson is affiliated with the following schools: